RWD90 ESTIMATING THE LIFETIME SURVIVAL AND QALYS OF TUMOR-TREATING FIELDS IN COMBINATION WITH TEMOZOLOMIDE FOR GLIOBLASTOMA USING A KOREAN POPULATION

patients shifting to Rakan KKM due to financial toxicity over the period of 2026-2035.Costs were limited to drug costs for chemo-, endocrine, and anti-HER2 therapies.All costs and financial outcomes, including Rakan KKM profit and patient out-of-pocket savings, were discounted at 3% annually.Results: The patient shift could generate RM 38,063,229 (USD8,458,495, 1USD=RM4.50)cumulative profit for MOH over ten years.Patients who switch to Rakan KKM may save an average of RM 26,285 (USD5,841) in out-of-pocket costs, a 59.2% reduction compared to private cancer care cost.From a health system perspective, the simulated scenario (private + Rakan KKM) could potentially save RM 428,215,819 (USD95,159,070) over ten years, compared to the base case (private only).Conclusions: Rakan KKM has the potential to be a cost-saving co-payment model for breast cancer treatment access.It potentially offers substantial savings for patients, contributes to MOH sustainability, and reduces system-wide healthcare costs.